Alaunos Therapeutics (NASDAQ:TCRT) Stock Falls 3% – Here’s Why

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares traded down 3% during mid-day trading on Monday. The company traded as low as $0.7761 and last traded at $0.7953. 48,122 shares traded hands during trading, a decline of 98% from the average session volume of 2,502,220 shares. The stock had previously closed at $0.82.

Analyst Ratings Changes

Separately, Weiss Ratings cut Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Alaunos Therapeutics Price Performance

The firm has a market cap of $2.20 million, a P/E ratio of -0.45 and a beta of -0.87. The stock’s 50 day moving average is $1.57 and its two-hundred day moving average is $2.17.

Alaunos Therapeutics (NASDAQ:TCRT) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc was a clinical-stage biotechnology company focused on developing genetically engineered T-cell therapies for cancer. Its primary research centered on T-cell receptor (TCR) therapies designed to recognize cancer-associated antigens and target solid tumors, an area that has historically been challenging for cell therapy developers.

The company’s technology portfolio included the Sleeping Beauty nonviral gene-transfer system, which was intended to introduce tumor-targeting TCRs into a patient’s T cells.